---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-104543"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T12:26:59.659300+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell amends Norbrook agreement; termination March 31, 2026 if FDA approval not received by Feb 28, 2026

## Summary
- Norbrook will complete manufacture of current in-process inventory.
- Agreement terminates March 31, 2026, subject to terms.
- If FDA approval for Re-Tain not received by Feb 28, 2026, agreement expires and Norbrook invoices Final Balance.
- Amendment continues other terms of the Development Services and Commercial Supply Agreement.

## SEC filing metadata
- accession: 0001213900-24-104543
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024104543/0001213900-24-104543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024104543/ea0223315-8k_immu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-104543
- JSON: https://secwatch.observer/filing/0001213900-24-104543.json
- Plain text: https://secwatch.observer/filing/0001213900-24-104543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.